AI assistant
NovoCure Ltd — Director's Dealing 2015
Oct 1, 2015
31949_dirs_2015-10-01_f8ac4468-7a78-4ce2-bc23-cb59195b2d6e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Novocure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2015-10-01
Reporting Person: Melnyk Peter M. (Chief Commercial Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Options to Buy Ordinary Shares | $3.44 | 2021-09-15 | Ordinary Shares (76869) | Direct | |
| Options to Buy Ordinary Shares | $6.72 | 2021-09-15 | Ordinary Shares (16260) | Direct | |
| Options to Buy Ordinary Shares | $7.03 | 2023-02-20 | Ordinary Shares (41391) | Direct | |
| Options to Buy Ordinary Shares | $7.48 | 2024-02-26 | Ordinary Shares (59130) | Direct | |
| Options to Buy Ordinary Shares | $14.37 | 2025-02-25 | Ordinary Shares (177390) | Direct |
Footnotes
F1: Fully vested and currently exercisable as of the date hereof.
F2: Options to buy 20,695 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 20,696 ordinary shares will vest and become exercisable in equal installments on each of February 20, 2016 and 2017, subject to Mr. Melnyk's continued employment through such dates.
F3: Options to buy 14,782 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 44,348 ordinary shares will vest and become exercisable in equal installments on each of February 26, 2016, 2017 and 2018, subject to Mr. Melnyk's continued employment through such dates.
F4: The options to buy 177,390 ordinary shares will vest and become exercisable in equal installments on each of February 25, 2016, 2017, 2018 and 2019, subject to Mr. Melnyk's continued employment through such dates.